Exit / M&A
Sunshine for heart failure
Profile of Sunshine Heart's C-Pulse heart pump, its US trials and trial funding plans, recalling the failure of fellow Australian device maker Ventracor during the global financial crisis.
CEO, Sunshine Heart, Inc.
Dave Rosa
Roles
| Role | Organisation | Sources |
|---|---|---|
| CEO (former) | Sunshine Heart, Inc. | GBS Ventures (14 Apr 2011), GBS Ventures (4 Feb 2011), GBS Ventures (4 Feb 2011) |
| Chief Executive (former) | Sunshine Heart, Inc | GBS Ventures (19 May 2011), GBS Ventures (30 Aug 2010), GBS Ventures (15 Jun 2010) |
Coverage
Stories naming Dave Rosa. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Funding announcement
Sunshine Heart Investor News
Sunshine Heart's CEO letter to investors reviews 2010: an A$13.2 million financing, C-Pulse trial growth at newly added hospitals, two senior R&D hires, and a website revamp.
Exit / M&A
Sunshine Heart Appoints New Director
ASX-listed heart device firm Sunshine Heart appoints US medtech executive Paul Buckman to its board, which now spans eight directors across Australia and the United States.
2 deals
Sunshine Heart successfully completes $9.5 million capital raising with close of non-renounceable rights offer
Sunshine Heart has completed an A$9.5m rights issue, following a September placement of A$3.7m. Backers GBS Venture Partners and CM Capital took full entitlements plus shortfall; proceeds fund US trials and European approval.
News
Sunshine Heart CEO Update
Sunshine Heart's chief executive reports to shareholders on the C-Pulse trial: halfway through its US feasibility study, first two minimally invasive implants completed and new hospitals in Australia, Canada and the US joining.
News
ASX Announcement First Minimally Invasive C-Pulse Procedure Performed at University of Louisville
A reposted ASX announcement from Sunshine Heart reports the first minimally invasive implant of its C-Pulse heart assist system, carried out in early June by a Louisville surgeon under a US FDA feasibility trial.